News
Better Together: Brandon Raabe’s Family Finds Connection in Celebrating His Life
Every Sunday, members of Brandon Raabe’s family log on to Google Meet from across the country. They trade ideas, divide up tasks, and plan a
Research Roundup: New Insights into More Personalized Neuroendocrine Cancer Care
By Anna C. Greene, PhD, NETRF Chief Scientific Officer Research is helping physicians make more informed decisions about how to treat and monitor neuroendocrine cancers.
A New Molecular Map of Lung NETs Shows the Power of a Research Ecosystem
By Anna C. Greene, PhD, NETRF Chief Scientific Officer Scientific progress rarely comes from a single experiment, or even a single research grant. It happens
NANETS and NETRF BTSI Grant Targets a Hidden Survival Mechanism in Aggressive Neuroendocrine Carcinoma
When chemotherapy stops working, patients and their care teams are left with few options. For people with poorly differentiated neuroendocrine carcinoma, that moment comes too
Trusting Your Intuition and Being Your Best Advocate: Tawnisha Jones’ Story
By Anne-Marie Green Director of Communications, NETRF Based in Columbus, Ohio, Tawnisha Jones has spent 11 years as a senior outpatient coder at the Ohio
The Power of International Collaboration: Notes from the INCA Summit
Elyse Gellerman, MHS, NETRF CEO When neuroendocrine cancer advocates from around the world gather, there’s tremendous energy and commitment to serving the needs of patients
When the Experts Don’t Speak the Same Language: The Neuroendocrine Cancer Terminology Problem
By Anna C. Greene, PhD, NETRF Chief Scientific Officer The language used to describe neuroendocrine cancer is complex, and it is not always used consistently.
You Ask, NETRF Answers: Why Do Some NET Treatments Work for Some People but Not Others?
By Anna C. Greene, PhD, NETRF Chief Scientific Officer People with neuroendocrine tumors (NETs) often ask why the same treatment can work very well for
FDA Approves New Radioligand Therapy for GEP-NETs
The FDA has approved lutetium Lu-177 dotatate injection (Bexlutry), a new option for adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Bexlutry is a radioligand
Chimeric Halts CAR T-cell Trial Enrollment, Shifts Approach
CDH17 Remains a Promising Target, Even as the CHM CDH17 Trial Changes Course The CHM CDH17 clinical trial, a CAR T-cell therapy built on research